Real-world progression-free survival of CDK4/6 inhibitors plus an aromatase inhibitor in HR-positive/HER2-negative metastatic breast cancer in United States routine clinical practice
Our study, the largest real-world CDK4/6i comparative effectiveness study to date, demonstrated no significant rwPFS differences between 1L palbociclib, ribociclib, and abemaciclib, plus AI, in patients with HR-positive/HER2-negative mBC.
Authors
- Filipa C. Lynce (ORCID: https://orcid.org/0000-0001-6615-7076)
- Giuseppe Curigliano (ORCID: https://orcid.org/0000-0003-1781-2518)
- Benjamin Li (ORCID: https://orcid.org/0000-0002-1783-7013)
- Aaron B. Cohen (ORCID: https://orcid.org/0000-0002-5598-9210)
- Melissa Estévez (ORCID: https://orcid.org/0000-0001-7800-0156)
- Lynn McRoy
- Adam Brufsky (ORCID: https://orcid.org/0000-0001-8080-7960)
- Xuan Liu (ORCID: https://orcid.org/0009-0007-3883-056X)
- Rachel M. Layman (ORCID: https://orcid.org/0000-0002-8663-0331)
- Hope S. Rugo (ORCID: https://orcid.org/0000-0001-6710-4814)
Institutions
- The University of Texas MD Anderson Cancer Center (US)
- Pfizer (United States) (US)
- Dana-Farber Cancer Institute (US)
- University of Pittsburgh Medical Center (US)
- Flatiron Health (United States) (US)
Publication Details
- Journal
- ESMO Open
- Published
- 2025-09-01
- DOI
- https://doi.org/10.1016/j.esmoop.2025.105570
- Citations
- 4
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 6.07